Merus NV (FRA:2GH)
€ 48.4 -0.4 (-0.82%) Market Cap: 3.34 Bil Enterprise Value: 3.04 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 57/100

Merus NV Interim Clinical Data Call Transcript

Jun 05, 2022 / 11:00PM GMT
Operator

Good day and thank you for standing by. Welcome to the Merus Investor Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. (Operator Instructions)

I would now like to hand the conference over to your first speaker today to Kathleen Farren, Investor Relations and Corporate Communications Manager. Please go ahead.

Kathleen Farren
Merus NV - IR & Corporate Communications Manager

Good evening everyone. Thank you for joining our call during this very busy ASCO weekend to discuss zenocutuzumab or Zeno and the data presented earlier today NRG1 fusion cancer.

The slide presentation we are presenting tonight is also available on our website at www.merus.nl. On this call we will also be making certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, and events and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot